Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of CLP 23.76 trillion. The enterprise value is 25.92 trillion.

Market Cap	23.76T
Enterprise Value	25.92T

Important Dates

The next confirmed earnings date is Wednesday, April 29, 2026.

Earnings Date	Apr 29, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.76M
Shares Outstanding	n/a
Shares Change (YoY)	+0.82%
Shares Change (QoQ)	-0.27%
Owned by Insiders (%)	0.20%
Owned by Institutions (%)	96.45%
Float	146.28M

Valuation Ratios

The trailing PE ratio is 20.41 and the forward PE ratio is 11.66.

PE Ratio	20.41
Forward PE	11.66
PS Ratio	2.67
PB Ratio	1.45
P/TBV Ratio	10.20
P/FCF Ratio	12.86
P/OCF Ratio	11.97
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.76, with an EV/FCF ratio of 14.03.

EV / Earnings	22.26
EV / Sales	2.92
EV / EBITDA	7.76
EV / EBIT	10.24
EV / FCF	14.03

Financial Position

The company has a current ratio of 2.68, with a Debt / Equity ratio of 0.36.

Current Ratio	2.68
Quick Ratio	1.70
Debt / Equity	0.36
Debt / EBITDA	1.79
Debt / FCF	3.25
Interest Coverage	10.56

Financial Efficiency

Return on equity (ROE) is 7.39% and return on invested capital (ROIC) is 11.19%.

Return on Equity (ROE)	7.39%
Return on Assets (ROA)	6.14%
Return on Invested Capital (ROIC)	11.19%
Return on Capital Employed (ROCE)	10.82%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	1.19B
Profits Per Employee	155.28M
Employee Count	7,500
Asset Turnover	0.34
Inventory Turnover	0.90

Taxes

In the past 12 months, Biogen has paid 237.44 billion in taxes.

Income Tax	237.44B
Effective Tax Rate	16.94%

Stock Price Statistics

The stock price has decreased by -26.10% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-26.10%
50-Day Moving Average	181.06
200-Day Moving Average	156.92
Relative Strength Index (RSI)	99.96
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.57

Income Statement

In the last 12 months, Biogen had revenue of CLP 8.91 trillion and earned 1.16 trillion in profits. Earnings per share was 7,917.77.

Revenue	8.91T
Gross Profit	7.03T
Operating Income	2.54T
Pretax Income	1.40T
Net Income	1.16T
EBITDA	3.25T
EBIT	2.54T
Earnings Per Share (EPS)	7,917.77

Balance Sheet

The company has 3.44 trillion in cash and 6.00 trillion in debt, giving a net cash position of -2,170.86 billion.

Cash & Cash Equivalents	3.44T
Total Debt	6.00T
Net Cash	-2,170.86B
Net Cash Per Share	n/a
Equity (Book Value)	16.45T
Book Value Per Share	112,024.37
Working Capital	5.07T

Cash Flow

In the last 12 months, operating cash flow was 1.99 trillion and capital expenditures -138.54 billion, giving a free cash flow of 1.85 trillion.

Operating Cash Flow	1.99T
Capital Expenditures	-138.54B
Depreciation & Amortization	697.99B
Net Borrowing	-265.72B
Free Cash Flow	1.85T
FCF Per Share	n/a

Margins

Gross margin is 78.95%, with operating and profit margins of 28.55% and 13.07%.

Gross Margin	78.95%
Operating Margin	28.55%
Pretax Margin	15.74%
Profit Margin	13.07%
EBITDA Margin	36.44%
EBIT Margin	28.55%
FCF Margin	20.73%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.82%
Shareholder Yield	-0.82%
Earnings Yield	4.90%
FCF Yield	7.77%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 2.97 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.97
Piotroski F-Score	6